• Recruiting

NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM

Updated: May 23


HO147SMM

NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

KRd

Rd


HO147SMM

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)


Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9) or Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).


Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland


Multiple Locations

Europe

 

ClinicalTrials.gov Identifier: NCT03673826


Official Title: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.


First Posted : September 17, 2018


Click here for details on ClinicalTrials.gov


HOVON HO147 MM

 

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Lenalidomide

 

Location


Europe

Czechia

Italy

Netherlands

Norway




Posts Archive